Trial Profile
A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 29 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 29 Sep 2009 New trial record.